Retatrutide

Retatrutide is a triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors, primarily utilized off-label for weight management and appetite regulation. While clinical trials for obesity and type 2 diabetes are ongoing, community users typically administer 1 mg doses, while clinician-led protocols range from 1 mg to 12 mg weekly via subcutaneous injection. Users occasionally report side effects including nausea, gastrointestinal distress, sleep disturbances, and injection-site reactions. Readers should note that the current evidence base for non-obesity indications remains thin, as many exploratory research areas lack published results despite significant discussion within the community.

Half-life~6 days

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsAnecdotalEfficacyAnecdotalSideEffectsPrice3.53.23.63.92.13.0

Research Evidence

Evidence shape

Retatrutide carries moderate clinical evidence, supported by 18 published human studies primarily focused on obesity and type 2 diabetes. While the research includes phase 3 trials and demonstrates measurable outcomes like weight loss and HbA1c reduction, the broader clinical picture remains thin, with only two of the 34 registered trials currently reporting results. Most of the 14 mapped indications rely on single-trial data or exploratory research, signaling that while the primary metabolic effects are well-documented in high-tier studies, the peptide’s efficacy across other conditions lacks sufficient verification.

Depthhow much
34 registered trials
22 completed · 2 with posted results · 11 recruiting / active · combined n=619
Breadthhow many areas
14 indications mapped
2 with results · 11 thin / exploratory · 1 animal-only · 7 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
2 blinded with results · AE rows aggregated from 2 trials · 11 linked publications on registered trials
Breadth and depth74 rows captured
Human
direct clinical signal
52
Animal
translational support
12
In vitro
mechanistic support
10
HighMediumLow

Anecdotal efficacy

Retatrutide side effects

Clinical research side effects

Anecdotal side effects

Price

Full buying guide →
1
Elevate Peptides
--
40 mg
$16.50
$0.412/mg
2
Chimera Peptides
CN
600 mg×10
$339.00
$0.56/mg
3
High Purity Peptides
Hong Kong
200 mg×10
$140.00
$0.7/mg
4
Saiyan Med
US
400 mg×10
$320.00
$0.8/mg
5
Uther
unknown
1000 mg×10
$800.00
$0.8/mg
6
Bio Hack London
GB
100 mg
$87.23
$0.872/mg

price offers can be sorted by column · 21 out-of-stock offers not shown

1-6 of 283

RETATRUTIDE dosing & protocol

How RETATRUTIDE is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 39
Typical dose
12 mg1 mg – 12 mg
typical
0
10 mg
20 mg
30 mg
40 mg
50 mg
distribution of 12 reported doses · darker = more
Frequency
weekly
Route
subQ

In the research‑trial tier, retatrutide was given subcutaneously at doses from 1 mg to 12 mg once weekly, with a typical dose of 12 mg per week.

39 sources
Clinician practice
Doctor & published-protocol guidance · n = 3
Starting dose
1 mg1 mg – 12 mg
start
0
10 mg
20 mg
30 mg
40 mg
50 mg
distribution of 5 reported doses · darker = more
By reported cadence· tap a row to filter the chart
Frequency
weekly
Route
subQ

Clinicians typically administer retatrutide subcutaneously at 12 mg once weekly, with reported doses ranging from 1 mg to 12 mg per week, based on three source reports.

3 sources
Anecdotal
Community-reported real-world use · n = 303
Typical dose
1 mg200 µg – 43.5 mg
typical
0
10 mg
20 mg
30 mg
40 mg
50 mg
distribution of 377 reported doses · darker = more
Frequency
unspecified
Route
subQ

Community users most often cite a typical dose of around 1 mg subcutaneously, though reported amounts span from 200 µg to 43.5 mg; frequency is unspecified in the majority of reports, with a minority noting weekly or twice‑weekly injections.

303 sources

Related peptides

SemaglutideTirzepatideSurvodutideAOD-9604CagrilintideOrforglipronLiraglutideExenatideTesamorelinEloralintideTesofensineMazdutide